Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin Succinate vs Tolterodine in Korean OAB Patients
NCT00189800Phase 3Completed
- Sponsor
- Astellas Pharma
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of solifenacin in overactive bladder (OAB), sponsored by Astellas Pharma. Primary endpoint: Mean change in daily micturition frequency at 12 weeks. Status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00189800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189800.